Why a Complete Response Is the Treatment Aim in Chronic Spontaneous Urticaria

por Bernstein, Jonathan A., Giménez-Arnau, Ana, Maurer, Marcus, Staubach, Petra, Barbier, Nathalie, Hua, Eva, Severin, Thomas, Laires, Pedro A., Balp, Maria-Magdalena
Publicado 2023

Comprehensive Assessment of Pharmacokinetics, Pharmacodynamics, and Tolerability of Ligelizumab in Healthy Volunteers and Patients with Chronic Spontaneous Urticaria to Optimize It...

por Ji, Yan, Calonder, Claudio, Kirsilä, Tiina, Burciu, Alis, Tisu, Matjaz, Joubert, Yolandi, Laurent, Nathalie, Hua, Eva, Patekar, Manmath, Drollmann, Anton, Woessner, Ralph
Publicado 2023

Ligelizumab improves sleep interference and disease burden in patients with chronic spontaneous urticaria

por Giménez‐Arnau, Ana, Maurer, Marcus, Bernstein, Jonathan, Staubach, Petra, Barbier, Nathalie, Hua, Eva, Severin, Thomas, Joubert, Yolandi, Janocha, Reinhold, Balp, Maria‐Magdalena
Publicado 2022

Ligelizumab improves angioedema, disease severity and quality-of-life in patients with chronic spontaneous urticaria()

por Metz, Martin, Bernstein, Jonathan A., Giménez-Arnau, Ana M., Hide, Michihiro, Maurer, Marcus, Sitz, Karl, Soong, Weily, Sussman, Gordon, Hua, Eva, Barve, Avantika, Barbier, Nathalie, Balp, Maria-Magdalena, Severin, Thomas
Publicado 2022